Anti-tumor peptide AP25 decreases cyclin D1 expression and inhibits MGC-803 proliferation via phospho-extracellular signal-regulated kinase-, Src-, c-Jun N-terminal kinase- and phosphoinositide 3-kinase-associated pathways

Hu,Jialiang; Cheng,Tao; Zhang,Lijun; Sun,Beicheng; Deng,Lei; Xu,Hanmei

doi:10.3892/mmr.2015.3912

September-2015 Volume 12 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 12 Issue 3

Full Size Image

Article

Anti-tumor peptide AP25 decreases cyclin D1 expression and inhibits MGC-803 proliferation via phospho-extracellular signal-regulated kinase-, Src-, c-Jun N-terminal kinase- and phosphoinositide 3-kinase-associated pathways

Authors:
- Jialiang Hu
- Tao Cheng
- Lijun Zhang
- Beicheng Sun
- Lei Deng
- Hanmei Xu
View Affiliations / Copyright

Affiliations: Key Laboratory of Modern Chinese Medicines, Ministry of Education, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China, Liver Transplant Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Pages: 4396-4402
|
Published online on: June 11, 2015

https://doi.org/10.3892/mmr.2015.3912
Expand metrics +

Abstract

The anti-tumor peptide AP25 is a prototype integrin antagonist, which exhibits anti‑angiogenic and anti‑tumor activity. The molecular mechanisms by which AP25 inhibits the growth of the MGC‑803 gastric carcinoma cell line were investigated in the present study. K‑ras specific RNA interference by lentiviral infection was successfully induced in MGC‑803 cells [MGC‑803 short hairpin (sh)RNA group] and the expression levels of K‑ras, phosphorylated extracellular signal‑regulated kinase (p-ERK) and cyclin D1 were observed to be markedly decreased. By contrast, AP25 caused cell cycle arrest of intact MGC‑803 cells and decreased p‑ERK and cyclin D1 expression levels. Of note, 0.4‑3.2 µM AP25 no longer inhibited MGC‑803 shRNA growth, indicating that AP25, at such concentrations, exerts its effect mainly through the Ras/Raf/mitogen-activated protein kinase kinase/ERK pathway, whereas at 25 µM, AP25 was able to inhibit MGC‑803 shRNA growth. Chemical inhibitors of Src, c‑Jun N‑terminal kinase (JNK) and phosphoinositide 3‑kinase (PI3K) were used to confirm that 25 µM AP25 inhibited growth of cells in the MGC‑803 shRNA group and activated intracellular signaling pathways with Src, JNK and PI3K as key enzymes. In conclusion, the present study revealed the signal transduction pathways activated by AP25 at low (0.4‑3.2 µM) or high (25 µM) concentrations. It also confirmed that integrins, when interacting with the freely moving ligand AP25 instead of immobilized extracellular matrix glycoproteins, are able to initiate cell signaling via similar pathways as in the latter case but with a reversed effect, to inhibit cell growth.

View Figures

View References

1	Yin R, Zheng H, Xi T and Xu HM: Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide. Bioconjug Chem. 21:1142–1147. 2010. View Article : Google Scholar : PubMed/NCBI
2	Stoker M, O'Neill C, Berryman S and Waxman V: Anchorage and growth regulation in normal and virus-transformed cells. Int J Cancer. 3:683–693. 1968. View Article : Google Scholar : PubMed/NCBI
3	Schwartz MA and Assoian RK: Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci. 114:2553–2560. 2001.PubMed/NCBI
4	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1 phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
5	Roovers K and Assoian RK: Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 22:818–826. 2000. View Article : Google Scholar : PubMed/NCBI
6	Gille H and Downward J: Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem. 274:22033–22040. 1999. View Article : Google Scholar : PubMed/NCBI
7	Takuwa N, Fukui Y and Takuwa Y: Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol. 19:1346–1358. 1999.PubMed/NCBI
8	Huang S, Chen CS and Ingber DE: Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol Biol Cell. 9:3179–3193. 1998. View Article : Google Scholar : PubMed/NCBI
9	Verma G, Bhatia H and Datta M: Gene expression profiling and pathway analysis identify the integrin signaling pathway to be altered by IL-1β in human pancreatic cancer cells: role of JNK. Cancer Lett. 320:86–95. 2012. View Article : Google Scholar : PubMed/NCBI
10	Niederlechner S, Baird C and Wischmeyer PE: P38MAP kinase, but not phosphoinositol-3 kinase, signal downstream of glutamine-mediated fibronectin-integrin signaling after intestinal injury. Nutr J. 12:882013. View Article : Google Scholar :
11	Lois C, Refaeli Y, Qin XF and Van Parijs L: Retroviruses as tools to study the immune system. Curr Opin Immunol. 13:496–504. 2001. View Article : Google Scholar : PubMed/NCBI
12	Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
13	Shields JM, Pruitt K, McFall A, Shaub A and Der CJ: Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10:147–154. 2000. View Article : Google Scholar : PubMed/NCBI
14	Yan J, Roy S, Apolloni A, Lane A and Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 273:24052–24056. 1998. View Article : Google Scholar : PubMed/NCBI
15	Deng L, Li G, Xi L, et al: Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol. 9:732009. View Article : Google Scholar : PubMed/NCBI
16	Olsson AK, Johansson I, Akerud H, et al: The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res. 64:9012–9017. 2004. View Article : Google Scholar : PubMed/NCBI
17	Dhanabal M, Volk R, Ramchandran R, Simons M and Sukhatme VP: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun. 258:345–352. 1999. View Article : Google Scholar : PubMed/NCBI
18	Hanai J, Dhanabal M, Karumanchi SA, et al: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 277:16464–16469. 2002. View Article : Google Scholar : PubMed/NCBI
19	Xu H, Pan L, Ren Y, et al: RGD-modified angiogenesis inhibitor HM-3 dose: dual function during cancer treatment. Bioconjug Chem. 22:1386–1393. 2011. View Article : Google Scholar : PubMed/NCBI
20	Garmy-Susini B and Varner JA: Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol. 6:155–163. 2008. View Article : Google Scholar : PubMed/NCBI
21	Cox D, Brennan M and Moran N: Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov. 9:804–820. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Anti-tumor peptide AP25 decreases cyclin D1 expression and inhibits MGC-803 proliferation via phospho-extracellular signal-regulated kinase-, Src-, c-Jun N-terminal kinase- and phosphoinositide 3-kinase-associated pathways

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles